NRP1 and malignant colon neoplasm: Therefore, modification of Sp family activity by butyrate and the potential of NRP-1 as an Sp1 target led us to investigate the ability of butyrate to modulate NRP-1 expression, with a view to providing an alternative therapy or chemopreventive strategy for colon cancer.